The purpose of this study is to evaluate the effectiveness and safety of stereotactic body radiation therapy (SBRT) in the management of oligometastatic recurrent prostate cancer (PCa) by means of a systematic review. Six databases were searched (CENTRAL, Embase, LILACS, PubMed, Scopus and Web of Science). Additionally, hand-searching and grey literature search were performed. The main outcomes were progression-free survival (PFS) and toxicity rates. Androgen deprivation therapy-free survival (ADT-FS), local control, pattern of recurrence, cancer-specific survival and overall survival were also assessed. Risk of bias and quality of evidence were judged with the aid of specific tools. Fourteen studies were included, involving 661 patients and 899 lesions (561 nodal, 336 bone, 2 liver). Median PFS and ADT-FS were around 1 to 3 years. Local control rates varied from 82 to 100% among researches with low risk of bias. Acute and late grade 2 toxicity was observed in 2.4% and 1.1% of the patients, respectively. One case of acute and two cases of late grade 3 toxicity were registered. Only one randomized study addresses this topic. Although it does not meet all the eligibility criteria, it is useful for the discussion. A quantitative analysis was not possible, nor were subgroup analyses, due to the significant heterogeneity of the interventions and outcomes reported. Longer follow-up period is required. SBRT seems to be a safe approach to metastatic lesions that might provide disease control and defer androgen deprivation therapy (ADT). Local control is better when higher radiation doses are employed.
Introduction
Oligometastasis is a term proposed to describe an intermediate state between disseminated and early disease. The number and site of metastatic tumours would be limited. Considering this concept, aggressive local treatment of the metastatic lesions could be applied with curative intent. 1, 2 Localized prostate cancer (PCa) is mostly treated with radical prostatectomy, external beam radiotherapy and/ or brachytherapy. 3 Following the primary treatment, if there is oligometastatic recurrence, there is no definitive consensus about how these patients should be managed. In the past decades, they have been mainly handled with palliative androgen deprivation therapy (ADT). 4, 5 However, this strategy may lead to several adverse effects, such as loss of libido, weight gain, cardiovascular disorders and gynaecomastia. These conditions can negatively impact the patients' quality of life. [6] [7] [8] [9] tomography/computed tomography (PET/CT) has contributed to the early detection of PCa recurrence. 10 PET/
CT plays an important role in precision medicine. It allows the identification of the exact site and dimensions of the metastases. In recent years, tests with high accuracy for PCa have been developed, as well as prostate-specific membrane antigen (PSMA) PET/CT. [11] [12] [13] [14] The positivity of PSMA PET/CT in patients with biochemical recurrence is associated with PSA levels (0-0.2 ng.ml: 42%, 0.2-1 ng/ ml: 58%, 1-2 ng/ml: 76%, >2 ng/ml: 95%). An analysis correlating its results with a histopathological assessment showed a summary sensibility and specificity of 80% and 97%, respectively.
14 Therefore, the oligometastatic recurrent PCa patients can now be identified and distinguished from those with disseminated disease.
Treatment techniques have also been improved, of which are noteworthy minimally invasive surgeries and stereotactic body radiation therapy (SBRT). SBRT uses precise targeting to deliver ablative radiation doses to tumours, while keeping a low toxicity profile. 15 As a result, interest in using local approaches to the direct treatment of metastasis has significantly increased. The clinical implication would be the long-term disease control, with the potential to postpone palliative systemic treatment until widespread progression. In addition, some patients might be cured of the disease. 16 Therefore, the main goal of the present systematic review is to evaluate the effectiveness and safety of SBRT in the management of oligometastatic recurrent PCa.
Methods
The systematic review was accomplished according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Checklist. 17 
Protocol and registration
The systematic review protocol was registered at the International Prospective Register of Systematic Reviews (PROSPERO, Centre for Reviews and Dissemination, University of York, Heslington, York, United Kingdom; and the National Institute for Health Research, London, United Kingdom) under the number CRD42017062556. 18 
Terminology definition
Oligometastatic recurrent PCa was defined based on the number of detectable lesions at the time of recurrence. Patients were considered who had five or fewer extracranial metastatic lesions, regardless of dimension. The primary disease has been treated and kept under control. 19, 20 Eligibility criteria
Studies investigating patients with oligometastatic recurrent PCa who received SBRT as direct treatment of metastasis were included. The articles provided an oncologic outcome (progression-free survival) and/or toxicity rates. There were no restrictions as to the year of publication or language of the study.
The following exclusion criteria were applied: (i) Previous reports of the same research group that presented the same population and outcomes. If multiple publications were found, the most recent one was selected; (ii) Insufficient data on oligometastatic recurrent PCa patients; (iii) Studies with less than five patients included; (iv) Studies with no data on PFS and toxicity; (v) Wrong type of publication/study design, such as conference abstracts, letters, literature reviews and personal opinions.
Information sources and search strategy
The studies were identified by using a search strategy adapted for each electronic database: Cochrane CEN-TRAL, Embase, Latin American and Caribbean Health Sciences (LILACS), PubMed, SCOPUS and Web of Science. A grey literature investigation was performed through Google Scholar. The searches were rerun just before the final analysis and the results were screened for eligible studies. Additional studies were identified by hand-searching the reference lists of candidate articles.
Appropriate truncation and word combinations were selected and adapted for each electronic database. All references were managed by the software EndNote (EndNote X7 Basic Thomson Reuters, New York, NY USA), and duplicates were removed. Electronic database searches were performed on March 23th, 2017. More information on the search strategies is provided in Data S1.
Study selection
The study selection was conducted in two phases. In phase 1, two reviewers (R.A.V. and E.T.F.) independently screened the titles and abstracts of potentially relevant studies and selected articles that appeared to meet the inclusion criteria based on their abstracts. In phase 2, the same reviewers independently read the full text of all selected articles and excluded studies that did not meet the inclusion criteria. Any disagreements, either in the first or second phase, were resolved by discussion and agreement between the two reviewers. In case a consensus could not be reached, a third author (P.E.D.R) was nominated to make a final decision. Studies excluded after full-text assessment and the reasons for their exclusion are listed in Data S2. For screening, data extraction and analysis, the web-based systematic review tool ©Covidence was used. 21 
Data collection process and items
Two reviewers (N.F.N. and R.Z.R.) independently collected the data from the selected articles: study characteristics (author, year of publication, country of origin of the study coordinator, temporality of data collection), population characteristics (sample size, age), disease characteristics (number and sites of lesions treated with SBRT, primary disease risk category, PSA value before SBRT,), primary treatment information (SBRT modality used, median time from primary treatment to SBRT), intervention characteristics (restaging method, SBRT treatment machine, use of ADT), median followup, oncologic outcomes: progression-free survival (PFS), local control, biochemical control, androgen deprivation therapy-free survival (ADT-FS), cancer-specific survival, overall survival, patterns of clinical recurrence, predictive factors of recurrence and toxicity (acute and late). A third reviewer (R.A.V.) crosschecked all the retrieved information. The expert became involved, when required, to make a final decision. When the needed data were not complete, the authors of the articles were contacted. Pertinent missing information was retrieved.
Risk of bias in individual studies
Methodological quality was assessed by using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Case Series, a 10-item validated quality appraisal tool. Judgements for each item were assessed as yes (Y), no (N), unclear (U) or not applicable (NA). 22 In order to support the overall appraisal, the number of Y judgements given for each study was counted, and a score was generated ranging from 0 to 10. A score of at least 7 was considered to determine low risk of bias in individual studies. Two reviewers (N.F.N. and R.Z.R.) conducted this process independently. Disagreements between the two reviewers were solved by a third investigator (R.A.V.).
Summary measures
Primary outcomes were PFS and toxicity rates. ADT-FS, local control, cancer-specific survival, overall survival, patterns of clinical recurrence after SBRT and prognostic factors were also assessed. Measures of frequency, means and medians were considered, as well as the median differences or standardized mean differences for continuous outcomes.
Synthesis of results
Overall data combination of the included studies was performed by a qualitative descriptive synthesis. Statistical data pooling was planned whenever studies were considered combinable and relatively homogeneous in relation to design, interventions and outcomes. Heterogeneity within studies was evaluated by considering clinical differences (participants, interventions and results), and methodological (design and risk of bias) and statistical (effect of studies) characteristics.
Risk of bias across studies
Quality of evidence was assessed by using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) standard. The criteria for this assessment were study design, risk of bias, imprecision, inconsistency, indirectness, presence of dose-response gradient, magnitude of effect and plausible biases that might reduce an apparent treatment effect. Quality of evidence should be characterized as high, moderate, low or very low. The table of findings was produced with the aid of the GRADE online software (GRADEpro GDT, Copenhagen, Denmark), provided by the GRADE Working Group, in association with Cochrane Collaboration and the Members of McMaster University.
23,24

Results
Study selection
The systematic literature search yielded 3669 citations from five electronic databases. After removing duplicates, 1895 articles remained. Results from Google Scholar added 30 more references. Three studies were identified by rerunning the searches prior to publication. No additional articles were found by cross-referencing. Following the screening of the titles and abstracts, the full texts of 41 studies were reviewed and 27 were excluded by using the eligibility criteria. The exclusion reasons with references are listed in Data S2. Finally, 14 articles [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] were selected for data extraction and subsequent qualitative synthesis. Figure 1 details the process of identification, inclusion and exclusion of studies.
Study characteristics
The descriptive characteristics of studies and patients are summarized in Table 1 .
All articles were published in the English language between 2011 and 2017, seven of which in Italy, two in Poland and two in Germany. Belgium, the Netherlands and the United States had 1 study each. One randomized controlled trial was found, but it did not meet all the eligibility criteria, so it was not included in the qualitative analysis. 39 Thirteen articles were single-arm case series/ cohort studies, and one case-control series, with five (36%) prospective [26] [27] [28] 33, 35 and nine (64%) retrospective researches. 25, [29] [30] [31] [32] 34, [36] [37] [38] Median follow-up period varied from 10.2 to 36.6 months ( Table 2) . Choline PET/CT was the most commonly used evaluation method and was present in all the studies. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] However, six of them [28] [29] [30] [31] 34, 36 allowed its substitution for less accurate tests (18F-FDG PET/CT, MRI, CT and/ or Bone Scan) in a minority of patients (<5%). The use of PSMA PET/CT was reported in only 1% of the patients.
Ten articles (with 64% of the patients) [26] [27] [28] [29] [30] 32, 33, 35, 37, 38 standardized some criteria for SBRT treatment failure, whether biochemical or clinical progression. The administration of ADT was not standardized at the time of SBRT (delivered in 38.7% of the patients) nor within disease progression. The use of other systemic therapies was not patterned either. Prophylactic pelvic irradiation at the time of SBRT was reported in 2% of the patients.
25,36
Records screened from databases (n = 38)
Additional studies identified from reference lists (n = 0) M1, patients with distant metastases; MRI, magnetic Resonance Imaging; N1, patients with metastases in regional nodes only; NCR, non-castration-resistant prostate cancer patients; PET/CT, positron emission tomography/computed tomography; PSMA, prostate-specific membrane antigen; RP, radical prostatectomy; SBRT, stereotactic body radiation therapy. Triggiani et al.
36
divided their cohort into two subgroups of patients: non-castration-resistant (i.e. oligorecurrent) and castration-resistant PCa (i.e. oligoprogressive). They described independent population characteristics and outcomes in each subgroup. On the other hand, Jereczek-Fossa et al. 26 in their 2012 series included not only oligometastatic, but also locally recurrent PCa patients. Data from this subgroup were not considered in the analysis. Also with respect to sample characteristics, Bouman-Wammes et al. 37 included, as a control group, retrospective data of 20 patients with oligometastatic disease not treated with SBRT. The current review considered only the data from the intervention group.
Risk of bias within studies
Risk of bias assessment is reported in Table 3 . Seven studies, containing 52% of patients, scored 7 or more 'yes' answers and were considered to be low risk of bias. 26, 28, 30, 32, 33, 35, 37 Particularly, given the retrospective nature of the researches, items 1, 4, and 5 (addressing inclusion criteria, consecutive inclusion and complete inclusion of participants, respectively) were the most common reasons for lowering the scores. In question 2, 'no' was the answer for studies that allowed restaging with methods other than PET/TC. Question 3 mainly analysed if the articles related a definition of treatment failure, a predefined follow-up schedule and the use of a standardized tool to grade toxicity.
Results of individual studies
The summary of the outcomes of individual studies is presented in Table 2 . A 2-year PFS rate was reported by seven articles, 25 30 showed a correlation between higher PSA values at the time of SBRT and lower PFS rates. One other study 35 showed a correlation between higher PSA values (≥4 ng/mL) and worse biochemical response.
The acute and late toxicity profile of individual studies, as well as a global evaluation, is described in Table 4 .
Synthesis of results
Overall, 661 patients (range 15-141) with 899 metastatic PCa lesions (range 19-209) were identified in the 14 articles. When described, two-thirds of the patients were classified as high risk PCa (D'Amico risk group) 40 at primary diagnosis. Median Gleason score was 7.
The sites of the 899 lesions treated with SBRT are shown in Figure 3 . The pattern of clinical recurrence after SBRT was not clearly reported by most of the articles, therefore only the data from four studies were summarized and shown in Figure 3 . 28, 32, 33, 35 Sites of recurrence, as well as the proportion of clinical relapses among all the participants from these four studies are also described in Figure 3 .
Various radiotherapy fractionation schedules were used. The most frequent were the administration of 30 Gy divided in three fractions (126 treatments), 24 Gy divided in three fractions (82 treatments), 24 Gy in a single dose (42 treatments) and 16 Gy in a single dose (38 treatments). All the fractionation schedules are listed in Data S3. Biologically Effective Dose (BED) with a/b = 3 Gy was calculated for all the reported schemes and is presented in Figure 4 .
Although the studies showed adequate homogeneity in the patients' characteristics, they presented considerable heterogeneity in the outcomes reported. Distinct definitions of treatment failure and different endpoints were employed, such as biochemical PFS, distant PFS or ADT-FS. The administration of ADT was not controlled in adjuvant (used in 37.8% of the patients) or progression settings. No measures of association for dichotomous variables were related, given the studies' design. Therefore, a quantitative analysis with meta-analysis was not performed.
Risk of bias across studies
Bearing in mind the studies' design, the quality of the evidence in the outcomes evaluated by the GRADE system was assessed as low (Data S4). The indirectness criteria have reduced the overall quality due to the lack of a balanced control group. The quality of evidence on acute toxicity was considered moderate, while the assessment of PFS, another critical outcome, decreased the overall grade to low. Even though there is a significant imprecision (PFS rates were mainly used, while most of the studies did not reach median PFS), the large effect presented and the lack of PSMA PET/CT (possibly reducing the demonstrated effect) kept its rate low. ADT-FS, not a critical outcome, was judged very low due to risk of bias, inconsistency and imprecision. Controversially, evidence on local control rate was considered high, owing to the large effect shown (rates around 100%), the dose-response relationship, and the existence of a factor possibly reducing the effect of the treatment (use of low radiation doses).
Discussion
Summary of evidence
The present systematic review investigated the available evidence to state the effectiveness and safety of SBRT for oligometastatic recurrent PCa management. The included studies showed high homogeneity in the patients' characteristics, but high heterogeneity in the outcomes reported. Above all, aggressive treatment of metastasis demands an accurate diagnostic method, that is, a highly sensitive and specific test. Most of the patients evaluated in this review were restaged with Choline-based PET/CT at the time of recurrence. This modality prevailed in the studies, but only one reported the use of PSMA PET/CT, which shows even greater accuracy in detecting PCa metastases. 11, 12, 41 This may have led to understaged diseases, in other words, a higher false negative rate. Then, some patients may have been undertreated. Novel researches within PSMA PET/CT may help to better select candidates for SBRT and direct treatment, however, whether this affects outcomes remains to be demonstrated. In 2015, Ost et al. 42 published a pooled analysis of all the available data up to that moment. 19, [25] [26] [27] [28] 43, 44 With a total of 119 patients, median distant clinical PFS was 21 months (95% confidence interval, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . Three-and five-year distant PFS were 31% and 15%, respectively. A BED > 100 Gy was associated with a higher local control rate when compared to lower doses (P = 0.01). In another similar analysis, the same author investigated the pattern of failure after SBRT, and suggested that most of the patients relapse in an oligometastatic manner. 45 Also, by analysing data from four studies 28, 32, 33, 35 in which the pattern of recurrence was clearly described, only 5.4% of the participants had disseminated disease at first relapse. These data favour the idea that patients could benefit from repeated SBRT sessions until widespread progression, improving disease control. A randomized phase II trial regarding this topic was recently published. It allowed both surgery (including extended pelvic lymph node dissection) and SBRT interventions, so it was not incorporated in the analysis. Sixty-two oligometastatic recurrent PCa patients were randomly assigned to surveillance or metastasis-directed therapy. The median follow-up time was 3 years. The median ADT-FS for control and intervention groups were 13 months and 21 months (hazard ratio, 0.60; log-rank, P = 0.11), respectively. The median biochemical PFS was better in the treatment arm (6 months vs. 10 months; hazard ratio, 0.53; P = 0.03), with a 100% local control in these patients. No grade 2 or higher toxicity was observed. A subgroup analysis showed a similar benefit for patients with nodal and non-nodal metastases. 39 These data are fairly consistent with the findings from the single-arm studies. However, the PFS endpoint could not be properly compared, as most of the studies reported distant, not biochemical PFS.
Among the data collected from the studies included in this review, median PFS varies between 1 and 3 years in studies with low risk of bias. This outcome was still not reached in some series due to short follow-up. Two-year PFS rates ranged from 30% to 63.5%. Many individuals did not present disease progression, but the follow-up period was too short to state the rate of patients who might have been cured of the metastatic disease.
The real benefit of disease control translates into the possibility of postponing the use of systemic therapies until widespread progression, keeping patients free from its adverse effects. In this context, data on ADT-FS were assessed. Despite only five studies having shown clear results, the data suggest SBRT could defer ADT for a median time of about 1-3 years, consistently with PFS. 28, 29, 33, [36] [37] [38] Overall survival is not a reliable outcome to measure the effectiveness of SBRT for oligometastatic recurrent PCa. These patients are long-term survivors and are frequently submitted to various systemic therapies over time.
The studies showed excellent local control rates of the metastases. It is noteworthy that all the studies in which fractionation schedules had a BED ≥ 108 Gy (a/ b = 3 Gy), no in-field recurrence was observed. That is to say a local control rate of 100% in the last followup. 26, 28, 33, 37 Although satisfactory, worse results were reported by studies presenting a significant number of patients treated with lower radiation doses. 25, 30, 31, [34] [35] [36] Fractionation schedules with higher doses, such as 30 Gy in three fractions or a single fraction ≥ 18 Gy, have proven effective and are good options for the management of these patients. Concerning adverse effects, very low rates of acute and late toxicity were registered. Among all the studies, only one patient had acute grade 3 toxicity. Two participants had late grade 3 events. It is worth noting that most of the data were retrospectively collected, so toxicity may have been underreported. The follow-up time was insufficient to properly assess late toxicity. The number of publications on the topic is rapidly increasing. Nine of the articles included were published from 2016 onwards. [30] [31] [32] [33] [34] [35] [36] [37] [38] There are at least three ongoing randomized trials. NCT02680587 (ORIOLE trial) is comparing SBRT to observational approach. NCT02685397 is studying the management of castration-resistant PCa. Finally, NCT02759783 (CORE study), which also includes breast and lung patients, is evaluating SBRT versus conventional care. This study was developed in the United Kingdom and currently has an Australian arm (TROG 16-03) where the use of PSMA PET/CT and patients' quality of life are also being assessed. There, a larger phase 3 PCa trial is planned if the results are encouraging.
Limitations
More data from randomized controlled trials are required. Furthermore, restaging with PSMA PET/CT could give more accurate results. Follow-up period of the patients is still short. No study had more than 4 years of median followup. That is insufficient time to evaluate the possibility of curing the metastatic disease or the late toxicity profile. Among the systemic therapies offered, the type, duration and timing of administration were not predefined. This contributes to the heterogeneity of the interventions. The outcomes reported were moderately heterogeneous. Studies varied on the endpoints and the definitions of treatment failure. A quantitative analysis was not possible, and nor were subgroup analyses (i.e. lesion sites, number of lesions). No studies reported quality of life assessment, which would be more important in studies with a control group, though.
Conclusions
Stereotactic body radiation therapy seems to be a safe modality to treat nodes and bone metastases on PCa. A longer follow-up time is required to assess late toxicity. Its use in the oligometastatic recurrent setting is promising, as it might provide control of the disease, with the possibility of deferring palliative androgen deprivation therapy. Local control rates are excellent, especially when higher radiation doses are employed (BED ≥ 108 Gy). Fractionation schedules such as 30 Gy in three fractions and a single fraction ≥ 18 Gy may be effective. The role of ADT at the time of SBRT remains unclear. Further investigation with randomized controlled trials is required. Future trials should control the use of ADT in adjuvant and progression settings. The use of PSMA PET/ CT is suggested in restaging. Quality of life assessment may help to clarify the benefits of this treatment.
